BlackRock Inc. - ARCUTIS BIOTHERAPEUTICS INC ownership

ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 117 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.30 and the average weighting 0.4%.

Quarter-by-quarter ownership
BlackRock Inc. ownership history of ARCUTIS BIOTHERAPEUTICS INC
ValueSharesWeighting
Q3 2023$21,348,329
-47.1%
4,020,401
-5.0%
0.00%0.0%
Q2 2023$40,324,995
-20.3%
4,231,374
-8.0%
0.00%0.0%
Q1 2023$50,580,992
-34.5%
4,598,272
-11.8%
0.00%
-50.0%
Q4 2022$77,171,020
-20.5%
5,214,258
+2.6%
0.00%
-33.3%
Q3 2022$97,110,000
-0.5%
5,081,744
+11.0%
0.00%0.0%
Q2 2022$97,561,000
+17.4%
4,578,153
+6.1%
0.00%
+50.0%
Q1 2022$83,124,000
-7.1%
4,315,802
+0.0%
0.00%0.0%
Q4 2021$89,471,000
-10.7%
4,313,864
+2.8%
0.00%
-33.3%
Q3 2021$100,241,000
-13.5%
4,195,926
-1.2%
0.00%0.0%
Q2 2021$115,945,000
-4.6%
4,248,620
+1.1%
0.00%
-25.0%
Q1 2021$121,562,000
+49.3%
4,201,959
+45.1%
0.00%
+33.3%
Q4 2020$81,437,000
+35.2%
2,895,054
+40.8%
0.00%
+50.0%
Q3 2020$60,253,000
+27.2%
2,056,386
+31.3%
0.00%0.0%
Q2 2020$47,372,000
+83.7%
1,566,574
+81.0%
0.00%
+100.0%
Q1 2020$25,786,000865,3090.00%
Other shareholders
ARCUTIS BIOTHERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
Frazier Life Sciences Management, L.P. 8,684,232$165,956,00012.78%
Bain Capital Life Sciences Investors, LLC 3,000,000$57,330,0006.84%
Pivotal bioVenture Partners Investment Advisor LLC 569,041$10,874,0003.97%
Logos Global Management LP 1,525,000$29,143,0003.58%
1492 Capital Management LLC 178,320$3,408,0002.45%
Cormorant Asset Management, LP 1,000,000$19,110,0001.34%
MPM BioImpact LLC 257,185$4,915,0001.16%
Orbimed Advisors 2,800,000$53,508,0000.99%
SECTORAL ASSET MANAGEMENT INC 220,985$4,223,0000.83%
Rubric Capital Management LP 472,047$9,021,0000.45%
View complete list of ARCUTIS BIOTHERAPEUTICS INC shareholders